News
Press Releases
November 16, 2021
Cedilla Therapeutics Expands Leadership Team with Key Appointments Across R&D And Finance
READ MORE »
October 25, 2021
Cedilla Therapeutics Completes $82.6M Series B Financing
READ MORE »
October 21, 2021
Cedilla Therapeutics Unveils Lead Programs for the Conditional Inhibition of TEAD and CDK2, Two High Value and Historically Undruggable Cancer Drivers
READ MORE »
April 21, 2021
Cedilla Therapeutics Appoints Chris Bowden, M.D. to its Board of Directors
READ MORE »
April 5, 2021
Cedilla Therapeutics Announces Appointment of Véronique Riethuisen as Chief Business Officer and Head of Finance
READ MORE »
November 30, 2020
Cedilla and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery
READ MORE »
October 13, 2020
Cedilla Therapeutics Announces $57.6 Million Series B Financing
READ MORE »
October 23, 2019
Cedilla Therapeutics Appoints Justin Birtz as Vice President, People and Culture
READ MORE »
May 14, 2019
Cedilla Therapeutics Appoints Delphine Collin, Ph.D., as Vice President, Biomolecular Sciences
READ MORE »
July 10, 2018
Cedilla Therapeutics Appoints Rosana Kapeller to Board of Directors
READ MORE »
June 28, 2018
Cedilla Therapeutics Expands Leadership Team with New Appointments to Direct Biology, Drug Discovery and Proteomics
READ MORE »
April 24, 2018
Third Rock Ventures Launches Cedilla Therapeutics with $56 Million Investment to Target Protein Stability Using Small Molecule Therapeutics
READ MORE »
MENU
About Us
Science
Pipeline
News
Join Our Team
Contact us